<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2018-12-21" updated="2019-11-02">
  <drugbank-id primary="true">DB14731</drugbank-id>
  <name>Tagraxofusp</name>
  <description>Tagraxofusp is an IL-3 conjugated truncated diphtheria toxin.[L4895] It is composed by the catalytic and translocation domains of diphtheria toxin fused via Met-His linker to a full-length human IL-3.[L4897, L4898] Tagraxofusp was developed by Stemline Therapeutics Inc and FDA approved on December 21, 2018, as the first therapy for blastic plasmacytoid dendritic cell neoplasm.[L4894] This drug achieved approval after being designed with the title of breakthrough therapy, priority review, and orphan drug status.[L4893] Tagraxofusp has been designed as an orphan drug in EU since November 2015.[L4898]</description>
  <cas-number>2055491-00-2</cas-number>
  <unii>8ZHS5657EH</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A40274</ref-id>
        <pubmed-id>23396213</pubmed-id>
        <citation>Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M: Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013 Jul;19(7):1006-12. doi: 10.1016/j.bbmt.2013.01.027. Epub 2013 Feb 5.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L4893</ref-id>
        <title>FDA news</title>
        <url>https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm629020.htm</url>
      </link>
      <link>
        <ref-id>L4894</ref-id>
        <title>FDA Label: Apadaz</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208653s002s003lbl.pdf</url>
      </link>
      <link>
        <ref-id>L4895</ref-id>
        <title>Oncology nursing news</title>
        <url>https://www.oncnursingnews.com/web-exclusives/fda-approves-tagraxofusperzs-for-blastic-plasmacytoid-dendritic-cell-neoplasm</url>
      </link>
      <link>
        <ref-id>L4896</ref-id>
        <title>Stemline therapeutics news</title>
        <url>https://ir.stemline.com/news-releases/news-release-details/stemline-therapeutics-announces-presentation-elzonristm</url>
      </link>
      <link>
        <ref-id>L4897</ref-id>
        <title>Blood journal</title>
        <url>http://www.bloodjournal.org/content/124/3/385?sso-checked=true</url>
      </link>
      <link>
        <ref-id>L4898</ref-id>
        <title>NHS reports</title>
        <url>http://www.io.nihr.ac.uk/wp-content/uploads/2018/09/12136-Tagraxofusp-for-BPDCN-V1.0-SEP2018-NON-CONF.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Tagraxofusp is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and pediatric patients over 2 years old. This treatment allows an alternative for the previous intense treatment which consisted of intensive chemotherapy followed by bone marrow transplantation.[L4893]&#13;
&#13;
BPDCN is a rare hematologic malignancy derived from plasmacytoid dendritic cells. It is characterized by the significantly increased expression of cells expressing CD4/CD56/CD123 and other markers restricted to plasmacytoid dendritic cells and a lack of expression of lymphoid, natural killer or myeloid lineage-associated antigens.[A40274] A key feature of the malignant cells is the overexpression of CD123, also known as interleukin-3 receptor, and the constant requirement of IL-3 for survival.[L4897]</indication>
  <pharmacodynamics>In vitro studies showed that BPDCN blasts are ultrasensitive to tagraxofusp by presenting IC50 values in the femtomolar scale.[L4897] One of the main physiological changes of BPDCN is the presence of elevated interferon alpha and to produce an inflammatory response. In trials with tagraxofusp and following cell depletion, there was observed a significant reduction in the levels of interferon alpha and interleukin 6.[L4896]&#13;
&#13;
In clinical trials, tagraxofusp reported complete remission and complete remission with a skin abnormality not indicative of active disease in 54% of the treated patients.[L4893]</pharmacodynamics>
  <mechanism-of-action>Tagraxofusp binds to cells expressing the IL-3 receptor and delivers in them the diphtheria toxin after binding. This is very useful as the malignant cells in BPDCN present a particularly high expression of IL-3 receptor (CD123+ pDC).[L4896] To be more specific, tagraxofusp gets internalized to the IL-3 receptor-expressing cell allowing for diphtheria toxin translocation to the cytosol and followed by the binding to ADP-ribosylation elongation factor 2 which is a key factor for protein translation. Once the protein synthesis is inhibited, the cell goes under a process of apoptosis.[L4895, L4897]&#13;
&#13;
As the apoptosis induction requires an active state of protein synthesis, tagraxofusp is not able to perform its apoptotic function in dormant cells.[L4897]</mechanism-of-action>
  <toxicity>There haven't been analysis observing the carcinogenic, mutagenic potential nor the effect on fertility. However, in studies performed in cynomolgus monkeys at an overdose rate of 1.6 times the recommended dose, it was observed severe kidney tubular degeneration. Similar studies at the recommended dose reported the presence of degeneration and necrosis of choroid plexus in the brain were. This effect seems to be progressive even 3 weeks after therapy withdrawal.[FDA label]</toxicity>
  <metabolism>For the metabolism, as tagraxofusp is a fusion protein, it is expected to get processed until small peptides and amino acids by the actions of proteases.</metabolism>
  <absorption>The reported Cmax in clinical trials was of around 23 ng/ml.[L4897] After a 15 min infusion of a dose of 12 mcg/kg the registered AUC and Cmax was 231 mcg.h/L and 162 mcg/L respectively.[FDA label]</absorption>
  <half-life>The reported half-life of tagraxofusp is of around 51 minutes.[L4897]</half-life>
  <protein-binding>Tagraxofusp is not a substrate of p-glycoprotein and other efflux pump proteins associated with multidrug resistance.[L4897]</protein-binding>
  <route-of-elimination>Tagraxofusp is eliminated as small peptides and amino acids. More studies need to be performed to confirm the main elimination route.</route-of-elimination>
  <volume-of-distribution>In BPDCN patients, the reported volume of distribution is of 5.1 L.[FDA label]</volume-of-distribution>
  <clearance>The clearance of tagraxofusp was reported to fit a mono-exponential model.[L4897] The reported clearance rate is reported to be of 7.1 L/h.[FDA label]</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor</synonym>
    <synonym language="english" coder="inn/usan">Tagraxofusp</synonym>
    <synonym language="english" coder="">tagraxofusp-erzs</synonym>
  </synonyms>
  <products>
    <product>
      <name>Elzonris</name>
      <labeller>Stemline Therapeutics, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>72187-0401</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>1000 ug/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA761116</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Elzonris</name>
      <ingredients>Tagraxofusp</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Recombinant Fusion Proteins</category>
      <mesh-id>D011993</mesh-id>
    </category>
    <category>
      <category>Recombinant Proteins</category>
      <mesh-id>D011994</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>1000 ug/1mL</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB14731.pdf?1545415934</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00012</drugbank-id>
      <name>Darbepoetin alfa</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tagraxofusp.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00016</drugbank-id>
      <name>Erythropoietin</name>
      <description>The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tagraxofusp.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>The risk or severity of Thrombosis can be increased when Peginesatide is combined with Tagraxofusp.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09107</drugbank-id>
      <name>Methoxy polyethylene glycol-epoetin beta</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tagraxofusp.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;&gt;tagraxofusp&lt;&lt;&lt;
MGADDVVDSSKSFVMENFSSYHGTKPGYVDSIQKGIQKPKSGTQGNYDDDWKGFYSTDNK
YDAAGYSVDNENPLSGKAGGVVKVTYPGLTKVLALKVDNAETIKKELGLSLTEPLMEQVG
TEEFIKRFGDGASRVVLSLPFAEGSSSVEYINNWEQAKALSVELEINFETRGKRGQDAMY
EYMAQACAGNRVRRSVGSSLSCINLDWDVIRDKTKTKIESLKEHGPIKNKMSESPNKTVS
EEKAKQYLEEFHQTALEHPELSELKTVTGTNPVFAGANYAAWAVNVAQVIDSETADNLEK
TTAALSILPGIGSVMGIADGAVHHNTEEIVAQSIALSSLMVAQAIPLVGELVDIGFAAYN
FVESIINLFQVVHNSYNRPAYSPGHKTRPHMAPMTQTTSLKTSWVNCSNMIDEIITHLKQ
PPLPLLDFNNLNGEDQDILMENNLRRPNLEAFNRAVKSLQNASAIESILKNLLPCLPLAT
AAPTRHPIHIKDGDWNEFRRKLTFYLKTLENAQAQQTTLSLAIF</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Molecular Formula</kind>
      <value>C2553 H4026 N692 O798 S16</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Tagraxofusp-erzs</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0001036</id>
      <name>Interleukin-3 receptor subunit alpha</name>
      <organism>Humans</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L4896</ref-id>
            <title>Stemline therapeutics news</title>
            <url>https://ir.stemline.com/news-releases/news-release-details/stemline-therapeutics-announces-presentation-elzonristm</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P26951" source="Swiss-Prot">
        <name>Interleukin-3 receptor subunit alpha</name>
        <general-function>Interleukin-3 receptor activity</general-function>
        <specific-function>This is a receptor for interleukin-3.</specific-function>
        <gene-name>IL3RA</gene-name>
        <locus>Xp22.3 or Yp11.3</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>306-325</transmembrane-regions>
        <signal-regions>1-18</signal-regions>
        <theoretical-pi>8.32</theoretical-pi>
        <molecular-weight>43329.585</molecular-weight>
        <chromosome-location>X, Y</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:6012</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>IL3RA</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M74782</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>186331</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P26951</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>IL3RA_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>IL-3 receptor subunit alpha</synonym>
          <synonym>IL3R</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002063|Interleukin-3 receptor subunit alpha
MVLLWLTLLLIALPCLLQTKEDPNPPITNLRMKAKAQQLTWDLNRNVTDIECVKDADYSM
PAVNNSYCQFGAISLCEVTNYTVRVANPPFSTWILFPENSGKPWAGAENLTCWIHDVDFL
SCSWAVGPGAPADVQYDLYLNVANRRQQYECLHYKTDAQGTRIGCRFDDISRLSSGSQSS
HILVRGRSAAFGIPCTDKFVVFSQIEILTPPNMTAKCNKTHSFMHWKMRSHFNRKFRYEL
QIQKRMQPVITEQVRDRTSFQLLNPGTYTVQIRARERVYEFLSAWSTPQRFECDQEEGAN
TRAWRTSLLIALGTLLALVCVFVICRRYLVMQRLFPRIPHMKDPIGDSFQNDKLVVWEAG
KAGLEECLVTEVQVVQKT</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020503|Interleukin-3 receptor subunit alpha (IL3RA)
ATGGTCCTCCTTTGGCTCACGCTGCTCCTGATCGCCCTGCCCTGTCTCCTGCAAACGAAG
GAAGGTGGGAAGCCTTGGGCAGGTGCGGAGAATCTGACCTGCTGGATTCATGACGTGGAT
TTCTTGAGCTGCAGCTGGGCGGTAGGCCCGGGGGCCCCCGCGGACGTCCAGTACGACCTG
TACTTGAACGTTGCCAACAGGCGTCAACAGTACGAGTGTCTTCACTACAAAACGGATGCT
CAGGGAACACGTATCGGGTGTCGTTTCGATGACATCTCTCGACTCTCCAGCGGTTCTCAA
AGTTCCCACATCCTGGTGCGGGGCAGGAGCGCAGCCTTCGGTATCCCCTGCACAGATAAG
TTTGTCGTCTTTTCACAGATTGAGATATTAACTCCACCCAACATGACTGCAAAGTGTAAT
AAGACACATTCCTTTATGCACTGGAAAATGAGAAGTCATTTCAATCGCAAATTTCGCTAT
GAGCTTCAGATACAAAAGAGAATGCAGCCTGTAATCACAGAACAGGTCAGAGACAGAACC
TCCTTCCAGCTACTCAATCCTGGAACGTACACAGTACAAATAAGAGCCCGGGAAAGAGTG
TATGAATTCTTGAGCGCCTGGAGCACCCCCCAGCGCTTCGAGTGCGACCAGGAGGAGGGC
GCAAACACACGTGCCTGGCGGACGTCGCTGCTGATCGCGCTGGGGACGCTGCTGGCCCTG
GTCTGTGTCTTCGTGATCTGCAGAAGGTATCTGGTGATGCAGAGACTCTTTCCCCGCATC
CCTCACATGAAAGACCCCATCGGTGACAGCTTCCAAAACGACAAGCTGGTGGTCTGGGAG
GCGGGCAAAGCCGGCCTGGAGGAGTGTCTGGTGACTGAAGTACAGGTCGTGCAGAAAACT
TGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF09240</identifier>
            <name>IL6Ra-bind</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>interleukin-3 receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPKK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to interleukin-3</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-epsilon receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fibroblast growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>interleukin-3-mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotrophin TRK receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Ras protein signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small GTPase mediated signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vascular endothelial growth factor receptor signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0009577</id>
      <name>ADP-ribosylation factor-like protein 2</name>
      <organism>Humans</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L4895</ref-id>
            <title>Oncology nursing news</title>
            <url>https://www.oncnursingnews.com/web-exclusives/fda-approves-tagraxofusperzs-for-blastic-plasmacytoid-dendritic-cell-neoplasm</url>
          </link>
          <link>
            <ref-id>L4897</ref-id>
            <title>Blood journal</title>
            <url>http://www.bloodjournal.org/content/124/3/385?sso-checked=true</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P36404" source="Swiss-Prot">
        <name>ADP-ribosylation factor-like protein 2</name>
        <general-function>Small GTP-binding protein which cycles between an inactive GDP-bound and an active GTP-bound form, and the rate of cycling is regulated by guanine nucleotide exchange factors (GEF) and GTPase-activating proteins (GAP). GTP-binding protein that does not act as an allosteric activator of the cholera toxin catalytic subunit. Regulates formation of new microtubules and centrosome integrity. Prevents the TBCD-induced microtubule destruction. Participates in association with TBCD, in the disassembly of the apical junction complexes. Antagonizes the effect of TBCD on epithelial cell detachment and tight and adherens junctions disassembly. Together with ARL2, plays a role in the nuclear translocation, retention and transcriptional activity of STAT3. Component of a regulated secretory pathway involved in Ca(2+)-dependent release of acetylcholine. Required for normal progress through the cell cycle.</general-function>
        <specific-function>Gtp binding</specific-function>
        <gene-name>ARL2</gene-name>
        <locus>11q13.1</locus>
        <cellular-location>Mitochondrion intermembrane space</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>20877.765</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:693</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P36404</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ARL2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms/>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0052004|ADP-ribosylation factor-like protein 2
MGLLTILKKMKQKERELRLLMLGLDNAGKTTILKKFNGEDIDTISPTLGFNIKTLEHRGF
KLNIWDVGGQKSLRSYWRNYFESTDGLIWVVDSADRQRMQDCQRELQSLLVEERLAGATL
LIFANKQDLPGALSSNAIREVLELDSIRSHHWCIQGCSAVTGENLLPGIDWLLDDISSRI
FTAD</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0052005|ADP-ribosylation factor-like protein 2 (ARL2)
ATGGGGCTCCTGACCATTCTGAAGAAGATGAAGCAGAAAGAGCGGGAGCTGCGACTGCTC
ATGCTTGGCCTGGACAATGCTGGAAAGACAACCATCCTGAAGAAGTTCAATGGGGAGGAC
ATCGACACCATCTCCCCAACGCTGGGCTTCAACATCAAGACCCTGGAGCACCGAGGATTC
AAGCTGAACATCTGGGATGTGGGTGGCCAGAAGTCCCTGCGGTCCTACTGGCGGAACTAC
TTTGAGAGCACCGATGGCCTCATCTGGGTAGTGGACAGCGCAGACCGCCAGCGCATGCAG
GACTGCCAGCGGGAGCTCCAGAGCCTGCTGGTGGAGGAGCGCCTGGCCGGAGCAACCCTC
CTCATCTTTGCTAATAAGCAGGACCTGCCTGGAGCACTGTCCTCTAACGCCATCCGCGAG
GTCCTGGAGCTGGACTCCATCCGCAGCCACCACTGGTGCATCCAGGGCTGCAGCGCCGTC
ACCGGGGAGAACCTGCTGCCGGGCATCGACTGGCTCCTGGATGACATTTCCAGCCGCATT
TTCACAGCTGACTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00025</identifier>
            <name>Arf</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>centrosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>focal adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial intermembrane space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial matrix</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleolus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>GTP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>GTPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>GTPase inhibitor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bicellular tight junction assembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>centrosome cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>maintenance of protein location in nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of GTPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell-substrate adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of microtubule polymerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of microtubule polymerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>tubulin complex assembly</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>